Compare ETV & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Eaton Vance Corporation Eaton Vance Tax-Managed Buy-Write Opportunities Fund of Beneficial Interest
Current Price
| Metric | ETV | STOK |
|---|---|---|
| Founded | 2005 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.9B |
| IPO Year | N/A | 2019 |
| Metric | ETV | STOK |
|---|---|---|
| Price | $14.14 | $28.59 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $34.50 |
| AVG Volume (30 Days) | 252.5K | ★ 812.5K |
| Earning Date | 01-01-0001 | 11-04-2025 |
| Dividend Yield | ★ 8.75% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.68 |
| Revenue | N/A | ★ $205,632,000.00 |
| Revenue This Year | N/A | $430.24 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $41.92 |
| Revenue Growth | N/A | ★ 1128.17 |
| 52 Week Low | $11.05 | $5.35 |
| 52 Week High | $13.50 | $38.69 |
| Indicator | ETV | STOK |
|---|---|---|
| Relative Strength Index (RSI) | 37.61 | 40.11 |
| Support Level | $14.39 | $25.21 |
| Resistance Level | $14.64 | $31.70 |
| Average True Range (ATR) | 0.13 | 2.09 |
| MACD | -0.03 | -0.58 |
| Stochastic Oscillator | 2.14 | 27.86 |
Eaton Vance Tax-Managed Buy-Write Opp is a United States-based diversified, closed-end management investment company. Its primary investment objective is to provide current income and gains. The secondary objective of the fund is capital appreciation. Under normal market conditions, the Fund invests at least 80% of its total assets in a diversified portfolio of common stocks, designated segments of which seek to exceed the total return performance of the S&P 500 and the NASDAQ-100.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.